OvaScience names development head
This article was originally published in Scrip
Executive Summary
Cambridge, Massachusetts-based OvaScience, a global fertility company focused on the discovery, development and commercialization of new treatment options, has appointed Dr Ravi Mehrotra chief corporate development officer. Dr Mehrotra joins OvaScience from Credit Suisse, where he was global head of biotechnology equity research since 2010, based in New York. Dr Mehrotra originally joined Credit Suisse in 2004 in London, UK, and served as head of European biotechnology and EMEA equity research.